COVID-19 updates - Get the latest information about Coronavirus and Iowa Heart Center

Galactic HF

Purpose of Study

Evaluate the effect of omecamtiv mecarbil/Amg 423 as compared with placebo in subjects with chronic heart failure with reduced ejection fraction receiving standard of care therapy.

Trial Status

In follow up

Eligibility Criteria

18-85 years old, history of chronic heart failure, NYHA class II to IV, LVEF < 35%, elevated BNP or NT-proBNP

Duration of Participation

Approximately 2-4 years

Contact Name: Megan Murphy, RN

Contact Phone: 515-235-5089

Contact Email: memurphy@iowaheart.com